Pharmacokinetic alterations of antimicrobials in the critically ill

Journal of Pharmacy Practice

Volumn 18, Issue 2, 2005, Pages 75-83

  Cook, Aaron M ^a,b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b Neurosurgery Critical Care   (United States)

Author keywords

Adult; Antimicrobials; Critical illness; Pharmacokinetics

Indexed keywords

ALUMINUM; ANTACID AGENT; ANTIINFECTIVE AGENT; BETA LACTAM; CALCIUM; CEFEPIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; FLUCONAZOLE; HYPERTENSIVE AGENT; IMIPENEM; KETOLIDE; LEVOFLOXACIN; LINEZOLID; MAGNESIUM; MEROPENEM; METHYLPREDNISOLONE; METOCLOPRAMIDE; MIDAZOLAM; NAFCILLIN; NALOXONE; OXAZOLIDINONE DERIVATIVE; PIPERACILLIN; TOBRAMYCIN; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN;

AREA UNDER THE CURVE; CRITICAL ILLNESS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSFORMATION; HOSPITAL INFECTION; HUMAN; INFECTION; INTENSIVE CARE UNIT; PHYSIOLOGY; PREDICTION; REVIEW; RISK FACTOR;

EID: 16344380591     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/0897190004273568     Document Type: Review

References (73)

1. Power BM, Forbes AM, van Heerden PV, Ilett KF. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet. 1998;34:25-56.
2. De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet. 2002;41:1135-1151.
3. Kennedy JM, Van Riji AM. Effects of surgery on the pharmacokinetic parameters of drugs. Clin Pharmacokinet. 1998;35:293-312.
4. Berger MM, Chiolero RL, Pannatier A, Cayeux MC, Tappy L. A 10-year survey of nutritional support in a surgical ICU: 1986-1995. Nutrition. 1997;13:870-877.
5. Young B, Ott L, Twyman D, et al. The effect of nutritional support on outcome from severe head injury. J Neurosurg. 1987;67:668-676.
6. Marik PE, Zaloga GP. Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med. 2001;29:2264-2270.
7. Mimoz O, Binter V, Jacolot A, et al. Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enterai feeding to critically ill patients. Intensive Care Med. 1998;24:1047-1051.
8. de Marie S, VandenBergh MFQ, Buijk SLCE, et al. Bioavailability of ciprofloxacin after multiple enterai and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections. Intensive Care Med. 1998;24:343-346.
9. Davis GA, Rapp RP, Kearney PA, Ensom MH. Pharmacokinetics of fluconazole in trauma patients with postpyloric feeding tubes. Ann Pharmacother. 2001;35:1492-1494.
10. Buijk SLCE, Gyssens IC, Mouton JW, Verbrugh HA, Touw DJ, Bruining HA. Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive Care Med. 2001;27:115-121.
11. Nguyen M, Beringer P, Wong-Beringer A, Louie S, Gill M, Gurevitch A. Effect of continuous enteral feedings on oral bioavailability of linezolid in hospitalized patients. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2003; Chicago, Ill.
12. Bosscha K, Nieuwenhuijs VB, Vos A, Samsom M, Roelofs JM, Akkermans LM. Gastrointestinal motility and gastric tube feeding in mechanically ventilated patients. Crit Care Med. 1998;26:1510-1517.
13. Dive A, Foret F, Jamart J, Bulpa P, Installe E. Effect of dopamine on gastrointestinal motility during critical illness. Intensive Care Med. 2000;26:901-907.
14. Reignier J, Said B, Perrin-Gachadoat D, Burdin M, Boiteau R, Tenaillon A. Erythromycin and early enteral nutrition in mechanically ventilated patients. Crit Care Med. 2002;30:1237-1241.
15. Jooste CA, Mustoe J, Collee G. Metoclopramide improves gastric motility in critically ill patients. Intensive Care Med. 1999;25:464-468.
16. Mixides G, Liebl MG, Bloom K. Enteral administration of naloxone for treatment of opioid-associated intragastric feeding intolerance. Pharmacotherapy. 2004;24:291-294.
17. Rebuck JA, Fish DN, Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy. 2002;22:1216-1225.
18. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge. Arch Intern Med. 1999;159:2449-2454.
19. Castro-Guardiola A, Viejo-Rodriguez A-L, Soler-Simon S, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med. 2001;111:367-374.
20. Ishihara H, Matsui A, Muraoka M, Tanabe T, Tsubo T, Matsuki A. Detection of capillary protein leakage by indocyanine green and glucose dilutions in septic patients. Crit Care Med. 2000;28:620-626.
21. Ishihara H, Otomo N, Suzuki A, Takamura K, Tsubo T, Matsuki A. Detection of capillary protein leakage by glucose and indocyanine green dilutions during the early post-burn period. Burns. 1998;26:525-531.
22. Young AB, Ott LG, Beard D, Dempsey RJ, Tibbs PA, McClain CJ. The acute-phase response of the brain-injured patient. J Neurosurg. 1988;69:375-380.
23. Camacho MT, Totapally B, Torbati D, Wolfsdorf J. Pulmonary and extrapulmonary effects of increased colloid osmotic pressure during endotoxemia in rats. Chest. 2001;120:1655-1662.
24. Bressolle F, Gouby A, Martinez J-M, et al. Population pharmacokinetics of amikacin in critically ill patients. Antimicrob Agents Chemother. 1996;40:1682-1689.
25. Barletta JF, Johnson SB, Nix DE, Nix LC, Erstad BL. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. J Trauma. 2000;49:869-872.
26. Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong ELY, Gin T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother. 2001;47:421-429.
27. Tang GJ, Tang JJ, Lin BS, Kong CW, Lee TY. Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol Scand. 1999;43:726-730.
28. Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med. 2001;29:385-391.
29. Brunner M, Pernerstorfer T, Mayer BX, Eichler HG, Muller M. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med. 2000;28:1754-1759.
30. Tomaselli F, Dittrich P, Maier A, et al. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis. Br J Clin Pharmacol. 2002;55:620-624.
31. Tegeder I, Schmidtko A, Brautigam L, Kirschbaum A, Geisslinger G, Lotsch J. Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther. 2002;71:325-333.
32. Bassi C, Pederzoli P, Vesentini S, et al. Behavior of antibiotics during human necrotizing pancreatitis. Antimicrob Agents Chemother. 1994;38:830-836.
33. McKindley DS, Boucher BA, Hess MM, Croce MA, Fabian TC. Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia. Pharmacotherapy, 1996;16:924-931.
34. Breilh D, Saux M-C, Delaisement C, et al. Pharmacokinetic population study to describe cefepime lung concentrations. Pulm Pharmacol Ther. 2001;14:69-74.
35. Boselli E, Breilh D, Duflo F, et al. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med. 2003;31:2102-2106.
36. Carcas AJ, Garcia-Satue JL, Zapater P, Frias-Iniesta J. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin Pharmacol Ther. 1999;65:245-250.
37. Maglio D, Nightingale CH, Nicolau DP. Extended interval aminoglycoside dosing: from concept to clinic. Int J Antimicrob Agents. 2002;19:341-348.
38. Takacs-Novak K, Jozan M, Hermecz I, Szasz G. Lipophilicity of antibacterial fluoroquinolones. Int J Pharm. 1992;79:89-96.
39. Groom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs, 2003;63:2769-2802.
40. Chien S-C, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother. 1997;41:2256-2260.
41. Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother. 1992;36:993-996.
42. Lipman J, Scribante J, Gous AGS, Hon H, Tshukutsoane S, Group BCS. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. Antimicrob Agents Chemother. 1998;42:2235-2239.
43. Zeitlinger MA, Dehghanyar P, Mayer BX, et al. Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. Antimicrob Agents Chemother. 2003;47:3548-3553.
44. Burgess DS, Hall RG, Hardin TC. In vitro evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against Pseudmonas aeruginosa. Diagn Microbiol Infect Dis. 2003;46:131-137.
45. Varela JE, Cohn SM, Brown M, Ward CG, Namias N, Spalding PB. Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries. J Antimicrob Chemother. 2000;45:337-342.
46. Capitano B, Mattoes HM, Shore E, et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest. 2004;125:965-973.
47. Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R. Intrapulmonary penetration of linezolid. J Antimicrob Chemother. 2003;51:1431-1434.
48. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003;124:1789-1797.
49. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
50. Trahan K, Gore DC. Nutritional support. Chest Surg Clin N Am. 2002;12:227-249.
51. Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci. 1999;88:1-7.
52. Brouwer KLR, Dukes GE, Powell JR. Influence of liver function on drug disposition. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3rd ed. Ann Arbor, Mich: Lippincott Williams & Wilkins; 1992:6.1-6.59.
53. Park GR. Molecular mechanisms of drug metabolism in the critically ill. Br J Anaesth. 1996;77:32-49.
54. Mishra A, Friedman HS, Sinha AK. The effects of erythromycin on the electrocardiogram. Chest. 1999;115:983-986.
55. Kushner J, Peckman H, Snyder C. Seizures associated with fluoroquinolones. Ann Pharmacother, 2001;35:1194-1198.
56. MacIntyre SS, Schultz D, Kushner I. Biosynthesis of C-reactive protein. Ann N Y Acad Sci. 1982;389:76-87.
57. Benet LZ, Hoener B-A. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115-121.
58. Scheife RT. Protein binding: what does it mean? Drug Intell Clin Pharm. 1989;23:S27-S31.
59. Edwards DJ, Lalka D, Cerra F, Slaughter RL. Alpha1-acid glycoprotein concentration and protein binding in trauma. Clin Pharmacol Ther. 1982;31:62-67.
60. Mann HJ, Townsend RJ, Fuhs DW, Cerra FB. Decreased hepatic clearance of clindamycin in critically ill patients with sepsis. Clin Pharm. 1987;6:154-159.
61. de Stoppelaar F, Stolk L, van Tiel F, Beysens A, van der Geest S, de Leeuw P. Meropenem pharmacokinetics and pharmacodynamics in patients with ventilator-associated pneumonia. J Antimicrob Chemother. 2000;46:150-151.
62. Triginer C, Izquierdo I, Fernandez R, et al. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med. 1990;16:303-306.
63. Zaske DE, Sawchuk RJ, Gerding DN, Strate RG. Increased dosage requirements of gentamicin in burn patients. J Trauma. 1976;16:824-828.
64. Garaud JJ, Regnier B, Inglebert F, Faurisson F, Bauchet J, Vachon F. Vancomycin pharmacokinetics in critically ill patients. J Antimicrob Chemother. 1984;14(suppl D):53-57.
65. Rybak MJ, Albrecht LM, Berman JR, Warbasse LH, Svensson CK. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother. 1990;34:792-795.
66. Jones EM, McMullin CM, Hedges AJ, et al. The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. J Antimicrob Chemother. 1997;40:121-124.
67. Garcia-Garmendia J-L, Ortiz-Leyba C, Garnacho-Montero J, et al. Risks factors for Acinetobacter baumanii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis. 2001;33:939-946.
68. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis. 1991;74:63S-70S.
69. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37:1073-1081.
70. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-12.
71. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol. 2003;43:1116-1123.
72. Kuti JL, Nightingale CH, Quintiliani R, Nicolau DP. Pharmacodymamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn Microbiol Infect Dis. 2002;44:51-57.
73. Albanese J, Leone M, Bruguerolle B, Ayem M-L, Lacarelle B, Martin C. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother. 2000;44:1356-1358.